A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 04 Oct 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.